# Grove Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/grove-biopharma

- Industry: Biotechnology
- Headquarters: Chicago, US
- Website: www.grovebiopharma.com
- Total disclosed funding: $34M
- Latest round: Series A (Apr 23, 2025)
- Investors on record: 8

## About

Grove Biopharma, Inc. is a US-based biotechnology company focused on pioneering Bionic Biologics™, a new class of synthetic therapeutics to combat intracellular protein-protein interactions for advanced treatment solutions.Founded in 2020 and headquartered in Chicago, US, Grove Biopharma, Inc. specializes in developing innovative synthetic therapeutics. The company has completed 3 deals, with their most recent Series A funding round on April 23, 2025, raising USD 30 mn from lead investor Data Collective and other notable participants. Paul Bertin, the founder, has a history of entrepreneurship in the biotech sector.Grove Biopharma specializes in the development of Bionic Biologics™, a novel class of synthetic therapeutics designed to target intracellular protein-protein interactions (PPIs). These therapeutics are hybrid biomolecules that combine elements of biological and synthetic design, enhancing functionality beyond what is naturally achievable. The core product offerings include customizable, multivalent biomolecules that facilitate membrane permeability, enabling them to reach intracellular targets. This innovative approach is aimed at addressing critical medical needs in patients suffering from cancer, neurodegenerative diseases, and rare disorders. As of now, the company has initiated clinical applications of these products, particularly in North America and Europe, catering to healthcare providers and research institutions focused on advanced therapeutic solutions.Grove Biopharma generates revenue through partnerships and collaborations with pharmaceutical companies, research institutions, and healthcare organizations interested in the therapeutic potential of its Bionic Biologics™ platform. Revenue transactions typically occur via formal agreements that may involve licensing fees, milestone payments, or revenue-sharing models based on the commercial success of developed therapeutics. The company’s flagship offerings operate on a contractual basis with clients who require specific therapeutic solutions tailored to complex diseases. While specific pricing plans for their products are not disclosed, the nature of their business relationships suggests a structured approach to collaboration that maximizes the value of their innovative therapeutic modalities.In April 2025, Grove Biopharma, Inc. raised USD 30 mn in Series A funding, led by Data Collective, to advance its proprietary platform and lead oncology programs into clinical development. The company is set to introduce new products designed for treating complex diseases in the coming year. Furthermore, Grove Biopharma plans to expand into new markets in Europe and Asia by late 2026, aiming to increase access to its innovative therapies globally.

## Funding rounds

- Series A, Apr 23, 2025, $30M — DCVC, Lilly, Portal Innovations, Walder Ventures, Gradiant Corporation, InVivium Capital, Mansueto Office
- Seed, May 10, 2021, $4M — Skydeck Capital, Portal Innovations, Walder Ventures

## Investors

- Skydeck Capital (https://capitalatlas.ai/funds/skydeck-capital) — Seed
- Portal Innovations (https://capitalatlas.ai/funds/portal-innovations) — Seed, Series A
- Walder Ventures (https://capitalatlas.ai/funds/walder-ventures) — Seed, Series A
- DCVC (https://capitalatlas.ai/funds/dcvc) — Series A
- Lilly — Series A
- Gradiant Corporation — Series A
- InVivium Capital (https://capitalatlas.ai/funds/invivium-capital) — Series A
- Mansueto Office — Series A